Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated I
- PDF / 459,552 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 16 Downloads / 174 Views
REVIEW
Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review Mourad F. Rezk . Burkhard Pieper
Received: June 10, 2020 Ó The Author(s) 2020
ABSTRACT Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major financial burden to societies and healthcare systems. The introduction of biologic medicines has contributed majorly to improving the clinical outcomes of IMIDs and as such these modalities have gained first- or second-line positions in a wide range of treatment guidelines from different international clinical societies. However, the high cost of these biologics traditionally limited their accessibility and delayed their initiation, leaving millions of patients with unmet medical needs for a more affordable and sustainable solution. The introduction of cost-efficient biosimilar anti-TNFs within Europe since 2013 has allowed more patients with IMIDs to access biologic therapies earlier and for longer, potentially altering the course of the disease into a milder phenotype and reducing the long-term disease burden. This review provides the latest evidence for the impact of biosimilars on patient outcomes and demonstrates their clinical value beyond a reduction in price. Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12602219. M. F. Rezk (&) B. Pieper Biogen International GmbH, Neuhofstrasse 30, 6340 Baar, Switzerland e-mail: [email protected]
Keywords: Access to treatment; Anti-TNF; Biosimilars; Disease burden; Early treatment; IMIDs; Maintenance of remission; Patient outcomes; Rheumatology
Key Summary Points Over the past 2 decades anti-tumour necrosis factor (TNF) biologics have revolutionized the management of chronic immune-mediated inflammatory diseases, but their relatively high cost has created unequal access for patients to these effective treatments and compromised therapeutic goals In addition to their positive impact on the sustainability of global healthcare, current evidence clearly shows that anti-TNF biosimilars are having an impact beyond cost reduction alone—increasing access to these essential biological therapies, improving patients’ outcomes and reducing disease burden However, all patients need to be able to take advantage of the full spectrum of benefits that biosimilars bring, which can be achieved by expeditious approvals, optimized market competition, and prompt and appropriate switching
Adv Ther
INTRODUCTION
ACCESS TO TREATMENT
Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that share common pathophysiological pathways and include rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and psoriasis (PsO) [1]. Globally, IMIDs have an incidence of 5–7% [2] and patients can often have multiple inflammatorydriven conditions at any one time [1]. Thus, IMIDs cause a large burden to patients, ph
Data Loading...
